ReleaseWire Connect

Guidebook Series for Investing provide detailed guidance of practical operation for overseas companies and investors how to apply for and secure approval from China's complex registration, investment project and business scope examination process for setting up foreign investment enterprises.

Current, historic and forecast values and trends for each packaging market, including individual categories- Comprehensive, country-specific analysis of the industry's market attractiveness, covering key trends and drivers- Competitive landscape and benchmarking with other key markets for each BRIC country- Description and analysis of the packaging categories and end-user markets for the packaging industry in each BRIC country- Porter's Five Forces Analysis of all individual categories and of the overall packaging industry for each BRIC country

The report also includes information on Cervical Cancer market. This report is built using data and information sourced from GlobalData’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

It provides market size and forecasts of the HNWI population. By leveraging the Wealth Insight HNWI Database, it provides key demographic breakdowns such as city specific data.

The global market for compression therapy was valued at $2 billion in 2011 and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 5% to $2.7 billion in 2018, driven by the growing incidence of venous disease due to chronic wounds, a growing elderly population, diabetes and repeated wound trauma. The increase in awareness of venous diseases, aided by campaigns from various venous disease forums, societies and educational materials, and the use of compression therapy products as a preventive measure is also expected to encourage market growth.

The global wind energy O&M market is expected to reach $13.3 billion in 2020 at a Compound Annual Growth Rate (CAGR) of 9.6% over the forecast period 2012-2020. Europe is the largest Operations and Maintenance (O&M) market, with an estimated market revenue of $2.8 billion in 2011, followed by North America, Asia Pacific and South America. The major factors driving the global wind energy O&M market are the increasing number of installations backed by financial incentives, capital subsidies and tax rebates; the component failure rates of turbines; and the ageing nature of the majority of wind turbines in operation. However, certain restraining factors also exist which are negatively impacting the growth of the O&M market, such as a lack of skilled manpower to perform maintenance and the cost of logistics. Over the historic period 2005-2011, the global market grew at a CAGR of 17.6% from 2005-2011 and reached $5.6 billion in 2011.

Our exports has calculated the global EOR technologies market – including investments in research and development (R&D) as well as spending on acquiring and using the technologies – to be worth $19.32bn in 2012. Growth over the ten year forecast period will be driven by a combination of factors, including high oil prices, ageing oil fields, rapidly escalating global energy demands, a desire to increase energy independence, increasing EOR opportunities in heavy oil and oil sands recovery, and a desire to reduce carbon dioxide (CO2) emissions.

In 2011, the micro & special motor industry saw the price of its most crucial raw material NdFeB soar, with the price of sintered NdFeB magnet increasing from RMB 107/kg at the beginning of 2011 to RMB 607/kg in July and to RMB 330/kg in early November. However, as raw materials only account for a very small proportion (less than 5%) of the cost of micro & special motor, the price hike didn’t promote the prices of micro & special motors or reduce the profits of micro & special motor manufacturers.

Major marketed drugs for RA are Enbrel (etanercept), Humira (adalimumab), Remicade (infliximab), Rituxan (rituximab), and Celebrex (celecoxib). With a sales figure of more than one billion, all five drugs are considered to be blockbusters. The endpoints used in their clinical trials are American College of Rheumatology (ACR) criteria. ACR response criteria consist of clinical symptoms and signs of inflammation including fatigue, joint pain, morning stiffness, joint tenderness, joint swelling, and Erythrocyte Sedimentation Rate (ESR). This is a used as a major endpoint in most of the clinical trials for RA.

The global wind energy O&M market is expected to reach $13.3 billion in 2020 at a Compound Annual Growth Rate (CAGR) of 9.6% over the forecast period 2012-2020. Europe is the largest Operations and Maintenance (O&M) market, with an estimated market revenue of $2.8 billion in 2011, followed by North America, Asia Pacific and South America. The major factors driving the global wind energy O&M market are the increasing number of installations backed by financial incentives, capital subsidies and tax rebates; the component failure rates of turbines; and the ageing nature of the majority of wind turbines in operation. However, certain restraining factors also exist which are negatively impacting the growth of the O&M market, such as a lack of skilled manpower to perform maintenance and the cost of logistics. Over the historic period 2005-2011, the global market grew at a CAGR of 17.6% from 2005-2011 and reached $5.6 billion in 2011.